Schrödinger, Inc. (NASDAQ:SDGR) Shares Sold by Tejara Capital Ltd

Tejara Capital Ltd decreased its holdings in shares of Schrödinger, Inc. (NASDAQ:SDGR - Free Report) by 21.6% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 80,907 shares of the company's stock after selling 22,328 shares during the quarter. Schrödinger accounts for about 1.0% of Tejara Capital Ltd's investment portfolio, making the stock its 27th biggest position. Tejara Capital Ltd owned 0.11% of Schrödinger worth $1,561,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. KBC Group NV boosted its holdings in shares of Schrödinger by 45.4% in the third quarter. KBC Group NV now owns 2,508 shares of the company's stock valued at $47,000 after purchasing an additional 783 shares during the period. Paradigm Asset Management Co. LLC purchased a new stake in shares of Schrödinger in the fourth quarter valued at approximately $50,000. Quarry LP boosted its holdings in shares of Schrödinger by 1,150.0% in the third quarter. Quarry LP now owns 2,825 shares of the company's stock valued at $52,000 after purchasing an additional 2,599 shares during the period. GAMMA Investing LLC boosted its holdings in shares of Schrödinger by 87.5% in the fourth quarter. GAMMA Investing LLC now owns 2,796 shares of the company's stock valued at $54,000 after purchasing an additional 1,305 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Schrödinger in the third quarter valued at approximately $102,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Insider Activity

In other news, CFO Geoffrey Craig Porges sold 5,491 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $21.76, for a total transaction of $119,484.16. Following the completion of the sale, the chief financial officer now owns 27,544 shares in the company, valued at approximately $599,357.44. This represents a 16.62 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 8.60% of the company's stock.

Remove Ads

Schrödinger Stock Performance

Schrödinger stock traded down $0.48 during mid-day trading on Friday, reaching $21.80. 1,485,705 shares of the company were exchanged, compared to its average volume of 744,751. The business has a fifty day moving average of $22.92 and a 200 day moving average of $20.76. The firm has a market cap of $1.59 billion, a P/E ratio of -9.32 and a beta of 1.62. Schrödinger, Inc. has a 12-month low of $16.67 and a 12-month high of $29.15.

Schrödinger (NASDAQ:SDGR - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. The company had revenue of $88.32 million for the quarter, compared to analysts' expectations of $83.20 million. Sell-side analysts predict that Schrödinger, Inc. will post -2.37 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. KeyCorp boosted their price target on Schrödinger from $25.00 to $27.00 and gave the company an "overweight" rating in a report on Friday, January 24th. Piper Sandler lowered their price target on Schrödinger from $50.00 to $45.00 and set an "overweight" rating for the company in a report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $32.29.

Schrödinger Company Profile

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.